Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 11/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663753 | 0.81 | COMT (0.59) | COMTLMNAPOLBSIGMAR1MC4R | |
| SCHEMBL18894648 | 0.77 | COMT (1.00) | COMT | |
| SCHEMBL2520788 | 0.75 | HDAC1 (0.63) | COMT | |
| SCHEMBL18894751 | 0.73 | COMT (0.66) | COMT | |
| SCHEMBL23777925 | 0.73 | COMT (0.90) | COMT | |
| SCHEMBL20691668 | 0.72 | LMNA (0.49) | COMTLMNAPOLBSIGMAR1MC4R | |
| SCHEMBL13381620 | 0.71 | LMNA (1.00) | LMNAPOLBSIGMAR1MC4R | |
| SCHEMBL1991840 | 0.71 | SIGMAR1 (0.52) | COMTLMNAPOLBSIGMAR1MC4R | |
| SCHEMBL1041303 | 0.70 | SIGMAR1 (1.00) | LMNAPOLBSIGMAR1MC4R | |
| SCHEMBL242970 | 0.70 | SIGMAR1 (1.00) | LMNAPOLBSIGMAR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-20200157111-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | IKZF2, WEE1, NOTUM | COMT 1973/4885LMNA 2492/4885POLB 2336/4885 |
| US-20200157111-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | IKZF2, WEE1, NOTUM | COMT 1973/4885LMNA 2492/4885POLB 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.